This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Elevance Health Shrinks to Grow Stronger: From Part D to Plan B?
by Kaibalya Pravo Dey
ELV exits Part D and trims Medicare Advantage markets, betting on stronger-margin plans to protect profitability.
UnitedHealth Reaffirms 2025 EPS Guidance: Time to Buy or Wait?
by Kaibalya Pravo Dey
UNH reaffirms its 2025 EPS outlook, but mounting costs, legal probes and valuation pressures cloud the path ahead.
Why Is Humana (HUM) Up 19.2% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Molina (MOH) Up 9.2% Since Last Earnings Report?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana, DrFirst Ties Up to Boost Statin Use in High-Risk Patients
by Zacks Equity Research
HUM partners with DrFirst to increase statin use in high-risk patients with diabetes and cardiovascular disease, aiming to close care gaps.
One Big Beautiful Bill Act: A Boon or Bane for Centene?
by Tanuka De
CNC faces both risk and reward from the One Big Beautiful Bill Act as Medicaid cuts collide with digital reform gains.
UnitedHealth Crashing After Q2 Shock: Should You Panic or Pounce?
by Kaibalya Pravo Dey
UNH plunges 12.9% after weak Q2 and slashing 2025 EPS guidance, sparking fears of deeper structural issues ahead.
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
by Zacks Equity Research
CI's Q2 results are likely to hinge on Evernorth's growth as core healthcare revenues and premiums face steep declines.
Can Humana Beat Q2 Earnings Estimates on Insurance Unit Strength?
by Zacks Equity Research
HUM's second-quarter earnings are likely to have witnessed strength in insurance premiums and Medicare, partly offset by rising costs and membership declines.
UnitedHealthcare Pressure Builds: Trouble Ahead for UNH's Q2 Earnings?
by Kaibalya Pravo Dey
UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.
UnitedHealth on Thin Ice Before Q2 Earnings: Should Investors Exit?
by Kaibalya Pravo Dey
UNH braces for a 27% earnings drop in Q2 as soaring medical costs, margin pressure and investor jitters weigh on performance.
Molina Healthcare Q2 Earnings Miss on Rising Medical Care Costs
by Zacks Equity Research
MOH's Q2 earnings lag estimates as rising medical care costs offset gains from premiums and rate hikes.
Compared to Estimates, Molina (MOH) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Molina (MOH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Molina (MOH) Q2 Earnings Miss Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of -0.36% and +5.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Molina (MOH) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Molina (MOH) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings
by Zacks Equity Research
MOH's Q2 revenues are set to rise nearly 10%, but rising costs cloud its profit outlook.
Analysts Estimate Centene (CNC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 17th
by Zacks Equity Research
FNF, MOH and CDZI have been added to the Zacks Rank #5 (Strong Sell) List on July 17, 2025.
Earnings Preview: Molina (MOH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth's Commercial Unit: A Stabilizer Amid Healthcare Turmoil?
by Zacks Equity Research
UNH relies on its growing commercial insurance business as pressures from Medicare mount and industry headwinds persist.
Implied Volatility Surging for Molina Healthcare Stock Options
by Zacks Equity Research
Investors need to pay close attention to MOH stock based on the movements in the options market lately.
Billing or Healing? UnitedHealth's HouseCalls Get a DOJ Checkup
by Kaibalya Pravo Dey
UNH faces a DOJ criminal probe over its HouseCalls billing, raising stakes for the Medicare Advantage giant.
Healthcare Hit Again: Molina Cuts Guidance, Echoing Centene and UNH
by Kaibalya Pravo Dey
MOH slashes 2025 EPS outlook by more than 10%, citing rising medical costs and echoing warnings from CNC and UnitedHealth.
Is Molina Healthcare (MOH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana Expands Medicaid Footprint With Virginia's Cardinal Care Win
by Zacks Equity Research
Cardinal Care taps HUM to offer its Healthy Horizons Medicaid plan, unlocking new growth in Virginia's healthcare market.